论文部分内容阅读
目的:观察双嘧达莫联合阿奇霉素治疗小儿支原体肺炎的临床疗效及不良反应。方法:将小儿支原体肺炎92例随机分为观察组和对照组各46例。两组均常规给予止咳、祛痰、退热等对症治疗,缺氧者给予鼻导管吸氧。对照组采用阿奇霉素治疗,10mg/(kg.d),静脉滴注;观察组在对照组治疗方案基础上加用双嘧达莫3~5 mg/(kg.d),分3次口服。7天为1个疗程。比较两组临床症状、体征消失时间,X线肺部阴影吸收时间及不良反应。结果:观察组临床症状、体征消失及X线肺部阴影吸收时间,与对照组比较均差异显著或非常显著(P<0.05,P<0.01);两组不良反应差异不显著(P>0.05)。结论:双嘧达莫联合阿奇霉素治疗小儿支原体肺炎临床疗效优于单用阿奇霉素治疗,且安全。
Objective: To observe the clinical efficacy and adverse reactions of dipyridamole combined with azithromycin in the treatment of children with mycoplasma pneumonia. Methods: 92 cases of children with mycoplasma pneumonia were randomly divided into observation group and control group, 46 cases each. Both groups were routinely given cough, expectorant, antipyretic and other symptomatic treatment, hypoxia were given nasal catheter oxygen. The control group was treated with azithromycin 10mg / (kg.d), intravenous drip; the observation group was treated with dipyridamole 3 ~ 5 mg / (kg.d) on the basis of the control group. 7 days for a course of treatment. Clinical symptoms, signs of disappearance, X-ray absorption time of lung shadow and adverse reactions were compared between the two groups. Results: The clinical symptoms and signs of the observation group disappeared and the absorption time of X-ray lung shadow in the observation group were significantly different from those in the control group (P <0.05, P <0.01). There was no significant difference in adverse reactions between the two groups (P> 0.05) . Conclusion: The clinical efficacy of dipyridamole combined with azithromycin in the treatment of children with mycoplasma pneumonia is better than that of azithromycin alone and is safe.